Genfit (NASDAQ:GNFT) Receives “Buy” Rating from HC Wainwright

Genfit (NASDAQ:GNFT)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $13.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 168.04% from the company’s previous close.

Genfit Stock Up 15.8 %

Shares of GNFT stock traded up $0.66 during trading hours on Friday, reaching $4.85. 115,300 shares of the stock were exchanged, compared to its average volume of 16,490. Genfit has a 12-month low of $2.89 and a 12-month high of $6.05. The company’s 50-day moving average price is $4.22 and its 200-day moving average price is $4.04. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.94 and a quick ratio of 2.94.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Genfit stock. Optiver Holding B.V. increased its holdings in shares of Genfit S.A. (NASDAQ:GNFT) by 2,229.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 82,359 shares of the company’s stock after acquiring an additional 78,823 shares during the period. Optiver Holding B.V. owned about 0.17% of Genfit worth $315,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 2.24% of the company’s stock.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.